QIAGEN powered by

Webinars and events

Loading Events

« All Events

  • This event has passed.

Whole genome sequencing (WGS), rapid WGS and ultra-rapid WGS for hereditary disorders – where speed matters

May 9, 2023 @ 1:00 pm - 2:30 pm

QIAGEN CLC LightSpeed Module delivers an ultra-fast, end-to-end hereditary NGS FASTQ to VCF pipeline. LightSpeed takes raw FASTQ files generated by paired-end 150 bp sequencing protocols and performs quality trimming, adapter trimming, read mapping, deduplication, local realignment, QC and germline variant calling.

More details: https://qiagen.showpad.com/share/Tue4ZxKsjAFetyoswbTfE

Cloud module: QIAGEN CLC Genomics Cloud computing software allows you to launch analyses from CLC Workbenches or CLC Servers for execution on AWS.
https://qiagen.showpad.com/share/ct2e3M9LfLazzuMMchqhG
• Overview of Genomics workbench and Platform
• Server / Cloud module overview
• Breaking the speed of light
• LightSpeed is arguably the fastest and cheapest-to-run hereditary FASTQ-to-VCF WGS pipeline available
• Benchmarks / comparisons
• Demo of lightspeed and cloud module for Fastq to vcf
• Install plugin
• Download reference(s)
• Execute workflow and review results

Details

Date: May 9, 2023
Time:
 1:00 pm - 2:30 pm
Register for event
Event Categories:
,

Venue

Virtual – Americas – EST
United States

Other

Category
Discovery, Webinar
Register for event

On-demand Webinars


  • Supercharge your AI in drug discovery with high-quality biomedical data

    If you’re working in pharma or biotech, you likely rely on artificial intelligence (AI) to help you identify new drug targets or plausible biomarkers for disease within large data sets. Yet AI alone isn’t enough. A large proportion of Biomedical data have errors and are unstructured. For AI models to provide reliable insights, the underlying data must be of ‘hig...

  • Scale up NGS bioinformatics analysis throughput with QIAGEN CLC Genomics cloud computing

    Scale your NGS analysis to match your sequencing throughput using our QIAGEN CLC Genomics cloud solution. In this webinar, you’ll learn about the flexible and powerful setup for running your NGS sequence analyses on Amazon Web Services (AWS). You’ll learn how to use QIAGEN CLC Genomics Workbench to customize workflows and send analyses to AWS Batch for execution. ...

  • QIAGEN Biomedical Knowledge Base: Data- and analytics-driven drug discovery

    Biomedical relationships knowledge is now required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many more applications. In this one-hour training, you’ll get an introduction to QIAGEN Biomedical Knowledge Base. You’ll learn how to tackle appli...

  • Part 1: AI-Powered Hereditary Disease Diagnostics: Closing the Gap in Clinical Exome Completeness

    Clinical exome sequencing (CES) is increasingly being adopted by small and mid-sized laboratories to diagnose genetic diseases, aid treatment decisions, and provide prognostic information. However, the exponential increase in genetic data generated from exome and genome panels poses significant workflow challenges. The ability to prioritize potentially pathogenic vari...

  • A breakthrough for rare disease: Completing the Clinical exome gap!

    In its latest release, QCI Interpret for Hereditary extends its market-leading content with further advancements in Artificial Intelligence (AI) for enhanced capabilities in clinical exome NGS testing. Now, with the addition of AI-derived literature references for rare disease genes, QCI Interpret provides complete exome coverage, on top of the existing unrivalled man...

  • What’s new in QIAGEN IPA Fall Release 2023?

    Interested in learning about new features and functionalities that have been added to IPA lately? During this webinar, we will highlight the updates from the QIAGEN IPA Fall Release and from previous releases from this year. Topics, amongst others, will be • Newly added findings and pathways • Reactome pathways • Artificial intelligence approves to pathways ...